Denecimig (Mim8) is a humanized bispecific IgG4κ antibody that mimics activated factor VIII function, promoting FIXa and FX assembly to enhance thrombin generation and hemostasis. It is applied in preclinical research for hemophilia A, including studies in relevant in vitro assays and in vivo bleeding models.